Exact Sciences Corporation

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-23 pm EDT 5-day change 1st Jan Change
63.53 USD +1.79% Intraday chart for Exact Sciences Corporation -0.52% -14.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Exact Sciences Corporation announced that it has received $266.75 million in funding CI
Sector Update: Health Care Stocks Advance Premarket Monday MT
Exact Sciences Names Aaron Bloomer CFO MT
Exact Sciences Appoints Aaron Bloomer as Chief Financial Officer, Effective from May 15, 2024 CI
Exact Sciences Corporation Announces Executive Changes CI
Exact Sciences Signs Debt Exchange Deal, Placement of Convertible Notes MT
Exact Sciences Corporation announced that it expects to receive $266.8 million in funding CI
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer CI
Transcript : Exact Sciences Corporation - Special Call
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing MT
Transcript : Exact Sciences Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM
Exact Sciences Insider Sold Shares Worth $356,302, According to a Recent SEC Filing MT
Exact Sciences Insider Sold Shares Worth $305,963, According to a Recent SEC Filing MT
Transcript : Exact Sciences Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M MT
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024 CI
Exact Sciences' Q4 Loss Narrows, Revenue Increases; Sets 2024 Revenue Forecast MT
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Exact Sciences Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Exact Sciences Sees 17% Growth in Q4 Revenue MT
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024 CI
Exact Sciences Corporation Provides Revenue Guidance for the Year Ended December 31, 2023 and 2024 CI
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Executive Vice President CI
Benchmark Upgrades Exact Sciences to Buy From Hold, Sets Price Target at $91 MT
Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI
Chart Exact Sciences Corporation
More charts
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
63.53 USD
Average target price
89.37 USD
Spread / Average Target
+40.67%
Consensus
  1. Stock Market
  2. Equities
  3. EXAS Stock
  4. News Exact Sciences Corporation
  5. Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M